Skip to main content

Table 2 Baseline characteristics in patients without diabetes

From: Cardiovascular risk in patients with and without diabetes presenting with chronic coronary syndrome in 2004–2016

 

2004–2006

n = 4847

2007–2009

n = 6104

2010–2012

n = 5547

2013–2016

n = 7042

Mean age, years (IQR)

66 (58–74)

 

67 (59–74)

 

67 (59–75)

 

68 (59–75)

 

Male sex

3554

73.3

4279

70.1

3732

67.3

4843

68.8

Family history

2290

47.2

2892

47.4

2687

48.4

3218

45.7

Active smoker

1293

26.7

1401

23.0

1275

23.0

1467

20.8

Comorbidity

        

Hypertension

2875

59.3

3949

64.7

3736

67.4

4488

63.7

Previous ischemic stroke

42

0.9

88

1.4

113

2.0

158

2.2

Atrial fibrillation

391

8.1

499

8.2

474

8.5

643

9.1

Peripheral artery disease

260

5.4

361

5.9

363

6.5

427

6.1

Heart failure

390

8.0

434

7.1

357

6.4

358

5.1

Renal disease

61

1.3

93

1.5

91

1.6

171

2.4

Mean eGFR, mL/min (IQR)

81 (66–96)

 

86 (70–102)

 

89 (74–104)

 

89 (74–104)

 

Median BMI, kg/m2 (IQR)

27 (24–29)

 

27 (24–30)

 

27 (24–29)

 

27 (24–29)

 

Modified Charlson Comorbidity Index score

        

0 points

3931

81.1

4568

74.8

3917

70.6

4799

68.1

1 point

607

12.5

929

15.2

893

16.1

1162

16.5

2 point

222

4.6

411

6.7

488

8.8

696

9.9

≥ 3 points

87

1.8

196

3.2

249

4.5

385

5.5

CAD extent

        

1 VD

1764

36.4

2321

38.0

2049

36.9

2661

37.8

2 VD

1236

25.5

1437

23.5

1141

20.6

1391

19.8

3 VD

1530

31.6

1386

22.7

1029

18.6

1132

16.1

Diffuse VD

317

6.5

960

15.7

1328

23.9

1858

26.4

Medication

Statin

        

Before

3141

64.8

4136

67.8

3667

66.1

4490

63.8

After

4347

91.4

5453

90.9

4879

89.1

6195

89.0

Aspirin

        

Before

3795

78.3

4621

75.7

4009

72.3

4717

67.0

After

4105

86.3

5067

84.5

4555

83.2

5500

79.0

ADP-inhibitor

        

Before

148

3.1

145

2.4

215

3.9

487

6.9

After

2540

53.4

2962

49.4

2535

46.3

3240

46.5

Vitamin K antagonists

        

Before

354

7.3

427

7.0

360

6.5

376

5.3

After

519

10.7

535

8.9

471

8.6

484

7.0

Non-vitamin K antagonists

        

Before

0

0.0

 < 5

0.0

38

0.7

268

3.8

After

0

0.0

 < 5

0.0

61

1.1

347

5.0

Beta-blocker

        

Before

3348

69.1

3674

60.2

2868

51.7

2756

39.1

After

3582

75.3

4219

70.3

3498

63.9

3707

53.2

ACE inhibitor

        

Before

1260

26.0

1643

26.9

1587

28.6

1590

22.6

After

1534

32.3

1947

32.5

1749

31.9

1694

24.3

ARB

        

Before

667

13.8

976

16.0

978

17.6

1479

21.0

After

731

15.4

1041

17.4

1057

19.3

1564

22.5

Thiazides

        

Before

891

18.4

1077

17.6

954

17.2

917

13.0

After

964

20.3

1111

18.5

930

17.0

914

13.1

Calcium channel blocker

        

Before

1601

33.0

1958

32.1

1741

31.4

1982

28.1

After

1777

37.4

2408

40.1

2211

40.4

2550

36.6

  1. Values are numbers and percentages unless otherwise stated. To preserve patient anonymity following Danish data regulations, cells with < 5 observations are presented as such
  2. ACE angiotensin converting enzyme, ADP adenosine diphosphate, ARB angiotensin-II receptor blocker, BMI body mass index, CAD coronary artery disease, eGFR estimated glomerular filtration rate, IQR inter-quartile range, VD vessel disease